Download PDF
Fortschr Neurol Psychiatr 2016; 84(S 01): S3-S7
DOI: 10.1055/s-0042-104501
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Epigenetik und die Parkinson’sche Krankheit

Epigenetics in Parkinson’s Disease
U. Wüllner
Further Information

Publication History

Publication Date:
14 June 2016 (online)

    Permissions and Reprints

Zusammenfassung

Epigenetische Mechanismen sind von entscheidender Bedeutung für die Genexpression. Während in der Basenabfolge der DNA-Sequenz die eigentliche genetische Information kodiert ist, regulieren die epigenetischen Modifikationen, insbesondere DNA-Methylierung und die Histonmodifikationen, den Zustand des Chromatins und damit die Transkription der Gene einer Zelle. Epigenetische Mechanismen bestimmen so die funktionellen Unterschiede genetisch identischer Zellen in mehrzelligen Organismen; sie steuern die Embryonalentwicklung und sind von entscheidender Bedeutung für Lernen und Gedächtniskonsolidierung. DNA-Methylierungsmuster werden prinzipiell vererbt, können aber durch Umweltbedingungen verändert und durch Mitose und Meiose hindurch weitergegeben werden. Methylierung der DNA bestimmt somit nicht nur die Ausprägung von verschiedenen Merkmalen, sondern vermittelt Umwelt-Gen-Interaktionen und trägt vermutlich auch zu Wirkungen und Nebenwirkungen von Medikamenten bei. Ebenso wie genetische Varianten mit sporadischen Erkrankungen assoziiert sind, könnten Varianten des Epigenoms beteiligt sein. Veränderte DNA-Methylierung könnte eine Rolle bei neuro-psychiatrischen Krankheiten spielen und die individuelle Variabilität der Parkinson-Krankheit mitbestimmen.

Abstract

The genetic information encoded in the DNA sequence provides a blueprint of the entire organism. The epigenetic modifications, in particular DNA methylation and histone modifications, determine how and when this information is made available and define the specific gene transcription pattern of a given cell. Epigenetic modifications determine the functional differences of genetically identical cells in multicellular organisms and are important factors in various processes from embryonic development to learning and memory consolidation. DNA methylation patterns are altered by environmental conditions and some alterations are preserved through mitosis and meiosis. Thus, DNA methylation can mediate environmental impact on health and disease, contributes to the severity of diseases and probably contributes to the effects and side effects of drugs. In addition to the classical monogenic epigenetic diseases such as Prader-Willi syndrome and Rett syndrome, recent data point to an epigenetic component also in sporadic neuro-psychiatric disorders.

Schlüsselwörter

DNA-Methylierung - Epigenetik - Synuklein - Biomarker

Key words

DNA methylation - epigenetics - synuclein - biomarker
 

  • Literatur

  • 1 Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 2003; 91: 133-142
    PubMedGoogle Scholar
  • 2 Wirdefeldt K, Adami HO, Cole P et al. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011; 1: 51-58
    PubMedGoogle Scholar
  • 3 Mullin S, Schapira AH. Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurol Clin 2005; 33: 1-17
    PubMedGoogle Scholar
  • 4 Weiner WJ. There is no Parkinson disease. Arch Neurol 2008; 65: 705-708
    PubMedGoogle Scholar
  • 5 Burke WJ, Kumar VB, Pandey N et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008; 115: 193-203
    CrossrefPubMedGoogle Scholar
  • 6 Tyson T, Steiner JA, Brundin P. Sorting Out Release, Uptake and Processing of Alpha-Synuclein During Prion-Like Spread of Pathology. J Neurochem 2015; epub DOI: 10.1111/jnc.13449.
    PubMedGoogle Scholar
  • 7 Nalls MA, Pankratz N, Lill CM et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet 2014; 46: 989-993
    CrossrefPubMedGoogle Scholar
  • 8 Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 2015; 31: 140-149
    CrossrefPubMedGoogle Scholar
  • 9 Berger SL, Kouzarides T, Shiekhattar R et al. An operational definition of epigenetics. Genes Dev 2009; 23: 781-783
    CrossrefPubMedGoogle Scholar
  • 10 Feinberg AP, Fallin MD. Epigenetics at the Crossroads of Genes and the Environment. JAMA 2015; 314: 1129-1130
    CrossrefPubMedGoogle Scholar
  • 11 Fischer A, Schneider A, Wüllner U. Epigenetic Mechanisms in Neurodegenerative Diseases. Akt Neurol 2015; 42: 393-401
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev 2015; 87: 3-14
    CrossrefPubMedGoogle Scholar
  • 13 Qureshi IA, Mehler MD. Understanding Neurological Disease Mechanisms in the Era of Epigenetics. JAMA Neurol 2013; 70: 703-710
    CrossrefPubMedGoogle Scholar
  • 14 Lardenoije R, Iatrou A, Kenis G et al. The epigenetics of aging and neurodegeneration. Prog Neurobiol 2015; 131: 21-64
    CrossrefPubMedGoogle Scholar
  • 15 Siegmund KD, Connor CM, Campan M et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2007; 2: e895
    CrossrefPubMedGoogle Scholar
  • 16 Murgatroyd C, Patchev AV, Wu Y et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci 2009; 12: 1559-1566
    CrossrefPubMedGoogle Scholar
  • 17 Li Y, Liu Y, Strickland FM et al. Age-dependent decreases in DNA methyltransferase levels and low transmethylation micronutrient levels synergize to promote overexpression of genes implicated in autoimmunity and acute coronary syndromes. Exp Gerontol 2010; 45: 312-322
    CrossrefPubMedGoogle Scholar
  • 18 Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915-926
    CrossrefPubMedGoogle Scholar
  • 19 Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 2003; 278: 4806-4812
    CrossrefPubMedGoogle Scholar
  • 20 Okano M, Bell DW, Haber DA et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-257
    CrossrefPubMedGoogle Scholar
  • 21 Janzen WP, Wigle TJ, Jin J et al. Epigenetics: Tools and Technologies. Drug Discov Today Technol 2010; 7: e59-e65
    CrossrefPubMedGoogle Scholar
  • 22 Noyer-Weidner M, Trautner TA. Methylation of DNA in prokaryotes. EXS 1993; 64: 39-108
    PubMedGoogle Scholar
  • 23 Moore LD, Le T, Fan G. DNA Methylation and Its Basic Function. Neuropsychopharmacology 2013; 38: 23-38
    CrossrefPubMedGoogle Scholar
  • 24 Maunakea AK, Chepelev I, Cui K et al. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Research 2013; 23: 1256-1269
    CrossrefPubMedGoogle Scholar
  • 25 Van der Wijst MGP, Venkiteswaran M, Chen H et al. Local chromatin microenvironment determines DNMT activity: from DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase. Epigenetics 2015; 10: 671-676
    CrossrefPubMedGoogle Scholar
  • 26 Torres IO, Fujimori DG. Functional coupling between writers, erasers and readers of histone and DNA methylation. Curr Opin Struct Biol 2015; 35: 68-75
    CrossrefPubMedGoogle Scholar
  • 27 Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004; 7: 847-854
    CrossrefPubMedGoogle Scholar
  • 28 Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA 2008; 105: 17046-17049
    CrossrefPubMedGoogle Scholar
  • 29 Nitert MD, Dayeh T, Volkov P et al. Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. Diabetes 2012; 61: 3322-3332
    CrossrefPubMedGoogle Scholar
  • 30 Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008; 9: 465-476
    CrossrefPubMedGoogle Scholar
  • 31 Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009; 8: 1056-1072
    CrossrefPubMedGoogle Scholar
  • 32 Skinner MK, Haque CGB, Nilsson E et al. Parental olfactory experience influences behavior and neural structure in subsequent generations. Nature Neurosci 2014; 17: 89-96
    PubMedGoogle Scholar
  • 33 Hughes V. Epigenetics: The sins of the father. Nature 2014; 507: 22-24
    CrossrefPubMedGoogle Scholar
  • 34 Ito S, D'Alessio AC, Taranova OV et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133
    CrossrefPubMedGoogle Scholar
  • 35 Gao Y, Chen J, Li K et al. Replacement of Oct4 by Tet1 during iPSC induction reveals an important role of DNA methylation and hydroxymethylation in reprogramming. Cell Stem Cell 2013; 12: 453-469
    CrossrefPubMedGoogle Scholar
  • 36 Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009; 324: 929-930
    CrossrefPubMedGoogle Scholar
  • 37 Al-Mahdawi S, Virmouni SA, Pook MA. The emerging role of 5-hyydroxymethylcytosine in neurodegenerative diseases. Frontiers in Neuroscience 2014; 8: 397
    PubMedGoogle Scholar
  • 38 Sherwani SI, Khan HA. Role of 5-hydroxymethylcytosine in neurodegeneration. Gene 2015; 570: 17-24
    CrossrefPubMedGoogle Scholar
  • 39 Riccio A. Dynamic epigenetic regulation in neurons: enzymes, stimuli and signaling pathways. Nat Neurosci 2010; 13: 1330-1337
    CrossrefPubMedGoogle Scholar
  • 40 Iwamoto K, Bundo M, Ueda J et al. Neurons show distinctive DNA methylation profile and higher interindividual variations compared with non-neurons. Genome Res 2011; 21: 688-696
    CrossrefPubMedGoogle Scholar
  • 41 Kozlenkov A, Roussos P, Timashpolsky A et al. Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites. 2014; 42: 109-127 DOI: 10.1093/nar/gkt838.
    PubMedGoogle Scholar
  • 42 De Boni L, Riedel L, Schmitt I et al. DNA methylation levels of α-synuclein intron 1 in the aging brain. Neurobiol Aging 2015; 36: 3334.e7-3334.e11
    CrossrefPubMedGoogle Scholar
  • 43 Takayama S, Dhahbi J, Roberts A et al. Genome methylation in D. melanogaster is found at specific short motifs and is independent of DNMT2 activity. Genome Res 2014; 24: 821-830
    CrossrefPubMedGoogle Scholar
  • 44 Wong NC, Ng J, Hall NE et al. Exploring the utility of human DNA methylation arrays for profiling mouse genomic DNA. Genomics 2013; 102: 38-46
    CrossrefPubMedGoogle Scholar
  • 45 Coppede F. Genetics and Epigenetics of Parkinson’s disease. The Scientific World Journal 2012; AID489830
    PubMedGoogle Scholar
  • 46 Habibi E, Masoudi-Nejad A, Abdolmaleky HM et al. Emerging roles of epigenetic mechanisms in Parkinson’s disease. Funct Integr Genomics 2011; 11: 523-537
    CrossrefPubMedGoogle Scholar
  • 47 Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006; 15: 3012-3023
    CrossrefPubMedGoogle Scholar
  • 48 Outeiro TF, Kontopoulos E, Altmann SM et al. Sirtuin 2inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson’s disease. Science 2007; 317: 516-519
    CrossrefPubMedGoogle Scholar
  • 49 Nicholas AP, Lubin FD, Hallett PJ et al. Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem 2008; 106: 486-494
    CrossrefPubMedGoogle Scholar
  • 50 Kidd SK, Schneider JS. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Research 2010; 1354: 172-178
    CrossrefPubMedGoogle Scholar
  • 51 Su M, Shi JJ, Yang YP et al. HDAC6 regulates aggresome-autophagy degradation pathway of α-synuclein in response to MPP+-induced stress. J Neurochem 2011; 117: 112-120
    CrossrefPubMedGoogle Scholar
  • 52 Pieper HC, Evert BO, Kaut O et al. Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiol Dis 2008; 32: 521-527
    CrossrefPubMedGoogle Scholar
  • 53 Hirsch EC, Breidert T, Rousselet E et al. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003; 991: 214-228
    PubMedGoogle Scholar
  • 54 Jowaed A, Schmitt I, Kaut O et al. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 2010; 30: 6355-6359
    CrossrefPubMedGoogle Scholar
  • 55 Matsumoto L, Takuma H, Tamaoka A et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 2010; 5: e15522
    CrossrefPubMedGoogle Scholar
  • 56 Wang Y, Wang X, Li R et al. A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons. CNS Neurosci Ther 2013; 19: 183-190
    CrossrefPubMedGoogle Scholar
  • 57 Gründemann J, Schlaudraff F, Liss B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 2008; 36: e38
    CrossrefPubMedGoogle Scholar
  • 58 Desplats P, Spencer B, Coffee E et al. α-synuclein sequesters Dnmt1 from the Nucleus. J Biol Chem 2011; 286: 9031-9037
    CrossrefPubMedGoogle Scholar
  • 59 Kaut O, Schmitt I, Wüllner U. Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 2012; 13: 87-91
    CrossrefPubMedGoogle Scholar
  • 60 Su X, Chu Y, Kordower JH et al. PGC-1α Promoter Methylation in Parkinson's Disease. PLoS One 2015; 10: e0134087
    CrossrefPubMedGoogle Scholar
  • 61 International Parkinson's Disease Genomics Consortium (IPDGC), Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 2011; 7: e1002142
    CrossrefPubMedGoogle Scholar
  • 62 Masliah E, Dumaop W, Galasko D et al. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics 2013; 8: 1030-1038
    CrossrefPubMedGoogle Scholar
  • 63 Davies MN, Volta M, Pidsley R et al. Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol 2012; 13: R43
    CrossrefPubMedGoogle Scholar
  • 64 Richter J, Appenzeller S, Ammerpohl O et al. No evidence for differential methylation of α-synuclein in leukocyte DNA of Parkinson's disease patients. Mov Disord 2012; 27: 590-591
    CrossrefPubMedGoogle Scholar
  • 65 Ai SX, Xu Q, Hu YC et al. Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease. J Neurol Sci 2014; 337: 123-128
    CrossrefPubMedGoogle Scholar
  • 66 Pihlstrøm L, Berge V, Rengmark A et al. Parkinson's disease correlates with promoter methylation in the α-synuclein gene. Mov Disord 2015; 30: 577-580
    CrossrefPubMedGoogle Scholar
  • 67 Song Y, Ding H, Yang J et al. Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson's disease patients. Neurosci Lett 2014; 569: 85-88
    CrossrefPubMedGoogle Scholar
  • 68 Tan YY, Wu L, Zhao ZB et al. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients. Parkinsonism Relat Disord 2014; 20: 308-313
    CrossrefPubMedGoogle Scholar
  • 69 Schmitt I, Kaut O, Khazneh H et al. L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro. Mov Disord 2015; 30: 1794-1801
    CrossrefPubMedGoogle Scholar
  • 70 Müller T, Woitalla D, Hauptmann B et al. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001; 308: 54-56
    CrossrefPubMedGoogle Scholar